RG-83852 

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRG-83852 
Drug Alias NameRG-83852
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody murine
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonists
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungHead and Neck Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesSanofiThe University Of Texas MD Anderson Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSanofiThe University Of Texas MD Anderson Cancer Center
Active IndicationsN/A
Inactive IndicationsCarcinoma, Non-Small-Cell LungHead and Neck Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A